Patients with multiple myeloma – What happens in second line after first-line refractory to daratumumab? Data from the German MYRIAM registry 25. Oktober 2024 Nusch, A., Burkhard-Meier, U., Jacobasch, L., Linde, H., Uhlig, J., Welslau, M., Tech, S., Medinger, T., Jänicke, M., Dechow, T., Einsele, H., Engelhardt, M., Knauf, W., Marschner, P., 2024 Oncol Res Treat (2024) 47 (Suppl. 2) (P741): p. 241 Download Real-world data on systemic treatment and biomarker testing in patients with advanced or metastatic endometrial cancer: results from the German registry platform SMARAGD Gratzke K., Decker T., Juhasz-Böss I., Zaiss M., Papathemelis T., Flade F., Haus A., Jaenicke M., Winter S., Georganoudis N., Marschner N., Stickeler E., Welt… Weiterlesen Centralized vs. decentralized testing for PD-L1 and HER2 in patients with metastatic gastric and esophageal cancer – Results from the German research platform SAPHIR Lordick, F., Bläker, H., Dechow, T., Binninger, A., Ringwald, K., de Buhr, R., von der Heyde, E., Zahn, M.-O., Nusch, A., Dörfel, S., Schulz, H.,… Weiterlesen